MiniPDX模型在晚期肺癌伴恶性胸腔积液患者治疗中的指导作用

Abstract
Figure/Table
References (28)
Related Citation (7)

Download: PDF (622 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the role of MiniPDX model in guiding the treatment of advanced lung cancer patients with malignant pleural effusion. Methods A total of 30 hospitalized patients with definite diagnosis of advanced lung cancer with malignant pleural effusion were selected from Shanghai International Medical Center from June 2017 to May 2019. They were randomly divided into the MiniPDX group and the control group at 1∶1, with 15 cases in each group. Both groups had received at least first-line treatment in the past and were complicated with malignant pleural effusion after relapse or disease progression. The pleural fluid of patients in the MiniPDX group was extracted to establish a MiniPDX model, and the sensitivity of the relevant treatment drugs was detected. The results of the study were used to guide the treatment of the patients in the group. The control group received only empirical treatment. The objective remission rate (ORR), disease control rate (DCR), progression free survival (PFS), and overall survival (OS) of the two groups were compared. Results Compared with the control group, ORR and DCR in MiniPDX group were improved, OS and PFS were prolonged, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Conclusion MiniPDX model has certain value in guiding the treatment of advanced lung cancer patients with malignant pleural effusion, and can improve the prognosis of patients.

Key words： Malignant pleural effusion MiniPDX Objective remission rate Overall survival Progression free survival

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Lin CHEN Yiwen JIANG Haosheng HUA Hongwei DING Gang▲

Cite this article:

JIA Lin CHEN Yiwen JIANG Haosheng HUA Hongwei DING Gang▲. Guiding role of MiniPDX model in the treatment of advanced lung cancer patients with malignant pleural effusion[J]. 中国医药导报, 2020, 17(20): 131-134.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I20/131

[1] 李金金，轩伟霞，张晓菊.恶性胸腔积液产生的机制研究进展[J].国际呼吸杂志，2018，38（10）：783-786.
[2] 汤钊猷.现代肿瘤学[M].2版.上海：上海医科大学出版社，2000：569-571.
[3] Chapuy B，Cheng H，Watahiki A，et al. Diffuse large B cell lymphoma patient derived xenograft models capture the molecular and biological heterogeneity of the disease [J]. Blood，2016，127（18）：2203-2213.
[4] Nicolle D，Fabre M，Simon-Coma M，et al. Patient derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management [J]. Hepatology，2016，64（4）：1121-1135.
[5] Xu Y，Zhang F，Pan X，et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance [J]. Cancer Commun（Lond），2018，38（1）：19.
[6] Gordon D，Axelrod DE. A reliable method to determine which candidate chemotherapeutic drugs effectively inhibit tumor growth in patient-derived xenografts（PDX）in single mouse trials [J]，Cancer Chemother Pharmacol，2019，84（6）：1167-1178.
[7] Zhang F，Wang W，Long Y，et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response [J]. Cancer Commun（Lond），2018，38（1）：60.
[8] Detterbeck FC，Chansky K，Groome P，et al. The IASLC Lung Cancer Staging Project： Methodology and Validation Used in the Development of Proposals for Revision of the Stage Classification of NSCLC in the Forthcoming（Eighth）Edition of the TNM Classification of Lung Cancer [J]. J Thorac Oncol，2016，11（9）：1433-1446.
[9] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumors：revised RECIST guideline [J]． Eur J Cancer，2009，45（2）：228-247.
[10] Antunes G，Neville E，Duffy J，et al. BTS guidelines for the management of malignant pleural effusions [J]. Torax，2003，58（Suppl 2）：ii29-ii38.
[11] Ryu JS，Ryu HJ，Lee SN，et al. Prognostic impact of minimal pleural effusion in non-small-cell lung cancer [J]. J Clin Oncol，2014，32（9）：960-967.
[12] Anderson CB，Philpott GW，Ferguson TB. The treatment of malignant pleural effusions [J]. Cancer，1974，33（4）：916-922.
[13] Hoi SY，Lin D，Gout PW，et al. Lessons from patient derived xenografts for better in vitro modeling of human cancer [J]. Adv Drug Deliv Rev，2014，79/80：222-237.
[14] Okada S，Vaeteewoottacharn K，Kariya R. Establishment of a Patient-Derived Tumor Xenograft Model and Application for Precision Cancer Medicine [J]. Chem Pharm Bull（Tokyo），2018，66（3）：225-230.
[15] Meohas W，Granato RA，Guimar?觔es JAM，et al. Patient-Derived Xenografts as a preclinical model for bone sarcomas [J]. Acta Ortop Bras，2018，26（2）：98-102.
[16] 周足力，陈修远，张鑫淼，等.肺癌人源性异种移植小鼠模型库的建立[J]，中华实验外科杂志，2019，36（1）：163-166.
[17] Zhao P，Chen H，Wen D，et al. Personalized treatment based on mini patient-derived xenografts and wes/rna sequencing in a patient with metastatic duodenal adenocarcinoma [J]. Cancer Commun（Lond），2018，38（1）：54.
[18] 王颖，吕雅蕾，高春晖，等.VEGF-A、C、D在恩度不同给药方式治疗晚期肺癌伴恶性胸腔积液中疗效预测的临床意义[J].河北医药，2019，2019，41（17）：2649-2652.
[19] 丁彦，周建荣，帅萍，等.VEGF、EGFR及CD40检测在鉴别良恶性胸腔积液中的价值[J].中国医药导报，2019， 16（20）：141-144.
[20] 周燕群，郭勇，杨笑奇，等.恩度联合顺铂腔内注射治疗肺癌合并恶性胸腔积液meta分析[J].实用肿瘤杂志，2018，33（6）：553-560.
[21] 宋军俊，戈伟.恩度联合复方苦参注射液治疗晚期非小细胞肺癌恶性胸腔积液的效果[J].中国医药导报，2018， 15（11）：143-146.
[22] 刘玉杰，田攀文.贝伐珠单抗治疗非小细胞肺癌所致恶性胸腔积液的研究进展[J].中国肺癌杂志，2019，22（2）：118-124.
[23] 戴冰，占美，徐珽.贝伐单抗不同给药方式治疗恶性胸腔积液有效性和安全性的Meta分析[J].中国药房，2020， 31（6）：734-739.
[24] 路欢欢，赵宝生，刘玉珍.胸腺肽联合奥沙利铂胸腔灌注治疗肺癌合并恶性胸腔积液的Meta分析[J].广西医科大学学报，2019，36（1）：36-41.
[25] 张吉发，刘希.奥沙利铂联合胸腺肽治疗肺癌合并恶性胸腔积液的疗效和安全性观察[J].中国医药科学，2018， 8（10）：36-38，138.
[26] 李博，袁秋贞，王岩，等.8种中药注射剂联合顺铂治疗恶性胸腔积液的网状Meta分析[J].中国医院药学杂志，2019，39（10）：1052-1057
[27] 石志永，娄广媛，古翠萍，等.热疗联合胸腔内顺铂化疗治疗晚期肺腺癌合并恶性胸腔积液的临床疗效分析[J].中国现代医生，2018，56（16）：60-63.
[28] Ghanim B，Rosenmayr A，Stockhammer P，et al. Tumor cell PD-L1 expression is prognostic in patients with malignant pleural effusion：the impact of C-reactive protein and immune-checkpoint inhibition [J]. Sci Rep，2020，10（1）：57-84.